Skip to main content
TipRanks
Go Ultimate75% OFF

Annexin Pharmaceuticals AB (ANNX) AI Stock Analysis

2 Followers
SE:ANNX

Annexin Pharmaceuticals AB

(Nasdaq OMX AB:ANNX)

Select Model
Rating:39Underperform
Price Target:SEK 8.50â–¼(-5.76% Downside)
Action:reiterated
Date:11/07/26

Annexin Pharmaceuticals' low overall score is primarily driven by its pre-revenue status, persistent net losses, and high cash burn, all of which elevate dilution risks. These fundamental headwinds are compounded by deeply negative valuation metrics and long-term technical downtrends, overshadowing a minor short-term price bounce.

Positive Factors
Debt-Free Balance SheetA debt-free balance sheet gives Annexin Pharmaceuticals greater flexibility while it advances its development programs. Without mandatory interest payments or refinancing obligations, more capital can be directed toward research and regulatory work, and the company is less exposed to leverage-driven financial distress.
Negative Factors
No RevenueThe absence of revenue confirms that Annexin Pharmaceuticals remains pre-commercial and cannot currently fund operations through customer demand. This increases dependence on successful clinical and regulatory progress before commercialization, extending the period in which shareholders must finance the business.

Annexin Pharmaceuticals AB (ANNX) vs. iShares MSCI Sweden ETF (EWD)

-80%-60%-40%-20%0%20%40%SE:ANNX-62.16%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 78.64M
Dividend Yield
―
Average Volume (3M)
9,474
Price to Earnings (P/E)
-2.0
Beta (1Y)
0.81
Revenue Growth
―
EPS Growth
7.33%
Country
Sweden
Employees
4
Sector
General
Sector Strength
55
Industry
Biotechnology

Annexin Pharmaceuticals AB Business Overview & Revenue Model

Company Description

Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects and...

Annexin Pharmaceuticals AB Financial Statement Overview

Summary

The company is in a pre-revenue stage with significant net losses and continuous cash burn. While a debt-free balance sheet provides some stability, rapidly depleting equity highlights a strong reliance on future external financing to sustain operations.

Income Statement

15Very Negative

Balance Sheet

45Neutral

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-48.00K-48.00K-193.00K-193.00K-193.00K-192.00K
EBITDA-42.01M-36.84M-50.20M-43.86M-40.72M-50.28M
Net Income-42.08M-36.89M-50.25M-44.05M-40.73M-52.14M
Balance Sheet
Total Assets17.66M30.16M19.04M26.76M36.68M52.79M
Cash, Cash Equivalents and Short-Term Investments14.44M27.39M16.34M21.41M31.11M49.48M
Total Debt000000
Total Liabilities5.33M5.22M5.32M7.95M6.53M6.06M
Stockholders Equity12.33M24.93M13.71M18.81M30.15M46.73M
Cash Flow
Free Cash Flow-41.22M-37.05M-50.23M-43.40M-41.16M-45.02M
Operating Cash Flow-41.22M-36.92M-50.23M-43.40M-41.16M-45.02M
Investing Cash Flow-178.00K-129.00K096.00K-260.00K0
Financing Cash Flow18.96M48.11M45.15M33.61M23.06M76.37M

Annexin Pharmaceuticals AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price9.02

Price Trends

50DMA9.12Negative
100DMA10.97Negative
200DMA12.57Negative

Market Momentum

MACD0.06Negative
RSI56.90Neutral
STOCH84.76Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ANNX, the sentiment is Neutral. The current price of 9.02 is above the 20-day moving average (MA) of 7.93, below the 50-day MA of 9.12, and below the 200-day MA of 12.57, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 56.90 is Neutral, neither overbought nor oversold. The STOCH value of 84.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ANNX.

Annexin Pharmaceuticals AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:ANNX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 369.63M1.9363.09%―――
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:BINVSE:BINV49NeutralSEK 193.46M-0.40-128.54%―-83.67%-50.29%
SE:XBRANESE:XBRANE46NeutralSEK 232.84M-6.25-11.52%―-38.80%-120.18%
SE:SPAGOSE:SPAGO42NeutralSEK 35.13M-1.10-87.37%―-97.52%31.31%
SE:BIOVIC.BSE:BIOVIC.B41NeutralSEK 86.35M-1.20-75.51%―56.06%63.95%
SE:ANNXSE:ANNX39UnderperformSEK 78.64M-2.05―――7.33%

* General Sector Average

Performance Comparison

-50%0%50%SE:ANNXSE:BINVSE:XBRANESE:BIOVIC.BSE:SPAGOSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ANNX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ANNXAnnexin Pharmaceuticals AB9.02-16.00-63.95%
SE:BINVBioInvent International AB2.94-28.31-90.59%
SE:XBRANEXbrane Biopharma AB11.301.8219.14%
SE:BIOVIC.BBiovica International AB Class B0.30-0.23-43.58%
SE:SPAGOSpago Nanomedical AB0.04-0.06-56.86%
SE:CANTACantargia AB1.31-1.86-58.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026